Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Drug Candidates Debut

ACS Meeting News: Perennial session serves up potential drugs for hepatitis, migraine, cancer, and type 2 diabetes

by Carmen Drahl
April 16, 2012 | A version of this story appeared in Volume 90, Issue 16

Medicinal chemists converged on San Diego for this spring’s American Chemical Society national meeting. They packed a ballroom to see the public debut of five drug candidate structures and hear the tales behind their discovery.

The presentations composed the Division of Medicinal Chemistry’s traditional “First Time Disclosures” session, which was supported by Gilead Sciences and organized by Albert J. Robichaud, chief scientific officer of Cambridge, Mass.-based Sage Therapeutics.

“In this time of tumult and uncertainty in the pharmaceutical world it is encouraging to see that scientists and drug discovery groups are still driving value for their organizations,” Robichaud told C&EN. “This session is an excellent example of the quality work that continues to come from the research teams of many of these companies that have experienced significant change.”

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.